Site-specific conjugation of a lanthanide chelator and its effects on the chemical synthesis and receptor binding affinity of human relaxin-2 hormone

Biochemical and Biophysical Research Communications

Volumn 420, Issue 2, 2012, Pages 253-256

  Shabanpoor, Fazel ^a   Bathgate, Ross A D ^a   Belgi, Alessia ^a   Chan, Linda J ^a   Nair, Vinojini B ^a   Wade, John D ^a   Hossain, Mohammed Akhter ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Circular dichroism; Lanthanide; Peptide; Protein; Relaxin; Solid phase synthesis

Indexed keywords

DIMETHYL SULFOXIDE; H2 RELAXIN RECEPTOR; LANTHANIDE; PENTETIC ACID; PHOSPHATE BUFFERED SALINE; RECEPTOR; SERELAXIN; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; BINDING AFFINITY; CIRCULAR DICHROISM; CONJUGATION; CONTROLLED STUDY; EMBRYO; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN SECONDARY STRUCTURE; RECEPTOR BINDING; SOLID PHASE SYNTHESIS; SOLUBILITY; SYNTHESIS;

AMINO ACID SEQUENCE; CHELATING AGENTS; HUMANS; LANTHANOID SERIES ELEMENTS; MOLECULAR SEQUENCE DATA; PENTETIC ACID; RECEPTORS, G-PROTEIN-COUPLED; RELAXIN; SOLID-PHASE SYNTHESIS TECHNIQUES;

EID: 84859425760     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.02.141     Document Type: Article

References (22)

1. Hisaw F. Experimental relaxation of the pubic ligament of the guinea pig. Proc. Soc. Exp. Biol. Med. 1926, 23:661-663.
2. Shabanpoor F., Separovic F., Wade J.D. The human insulin superfamily of polypeptide hormones. Vitam. Horm. 2009, 80:1-31.
3. Eigenbrot C., Randal M., Quan C., Burnier J., O'Connell L., Rinderknecht E., Kossiakoff A.A. X-ray structure of human relaxin at 1.5A. Comparison to insulin and implications for receptor binding determinants. J. Mol. Biol. 1991, 221:15-21.
4. Bathgate R.A., Ivell R., Sanborn B.M., Sherwood O.D., Summers R.J. International Union of Pharmacology LVII: recommendations for the nomenclature of receptors for relaxin family peptides. Pharmacol. Rev. 2006, 58:7-31.
5. Bullesbach E.E., Schwabe C. The relaxin receptor-binding site geometry suggests a novel gripping mode of interaction. J. Biol. Chem. 2000, 275:35276-35280.
6. Bullesbach E.E., Yang S., Schwabe C. The receptor-binding site of human relaxin II. A dual prong-binding mechanism. J. Biol. Chem. 1992, 267:22957-22960.
7. Park J.I., Semyonov J., Yi W., Chang C.L., Hsu S.Y. Regulation of receptor signaling by relaxin A chain motifs: derivation of pan-specific and LGR7-specific human relaxin analogs. J. Biol. Chem. 2008, 283:32099-32109.
8. Hsu S.Y., Nakabayashi K., Nishi S., Kumagai J., Kudo M., Sherwood O.D., Hsueh A.J. Activation of orphan receptors by the hormone relaxin. Science 2002, 295:671-674.
9. Sherwood O.D. Relaxin's physiological roles and other diverse actions. Endocr. Rev. 2004, 25:205-234.
10. Mookerjee I., Solly N.R., Royce S.G., Tregear G.W., Samuel C.S., Tang M.L. Endogenous relaxin regulates collagen deposition in an animal model of allergic airway disease. Endocrinology 2006, 147:754-761.
11. Koos R.D., Kazi A.A., Roberson M.S., Jones J.M. New insight into the transcriptional regulation of vascular endothelial growth factor expression in the endometrium by estrogen and relaxin. Ann. NY Acad. Sci. 2005, 1041:233-247.
12. Palejwala S., Tseng L., Wojtczuk A., Weiss G., Goldsmith L.T. Relaxin gene and protein expression and its regulation of procollagenase and vascular endothelial growth factor in human endometrial cells. Biol. Reprod. 2002, 66:1743-1748.
13. Teerlink J.R., Metra M., Felker G.M., Ponikowski P., Voors A.A., Weatherley B.D., Marmor A., Katz A., Grzybowski J., Unemori E., Teichman S.L., Cotter G. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet 2009, 373:1429-1439.
14. Teichman S.L., Unemori E., Teerlink J.R., Cotter G., Metra M. Relaxin: review of biology and potential role in treating heart failure. Curr. Heart Fail. Rep. 2010, 7:75-82.
15. Feng S., Agoulnik I.U., Truong A., Li Z., Creighton C.J., Kaftanovskaya E.M., Pereira R., Han H.D., Lopez-Berestein G., Klonisch T., Ittmann M.M., Sood A.K., Agoulnik A.I. Suppression of relaxin receptor RXFP1 decreases prostate cancer growth and metastasis. Endocr. Relat. Cancer 2010, 17:1021-1033.
16. Sudo S., Kumagai J., Nishi S., Layfield S., Ferraro T., Bathgate R.A., Hsueh A.J. H3 relaxin is a specific ligand for LGR7 and activates the receptor by interacting with both the ectodomain and the exoloop 2. J. Biol. Chem. 2003, 278:7855-7862.
17. Shabanpoor F., Hughes R.A., Bathgate R.A., Zhang S., Scanlon D.B., Lin F., Hossain M.A., Separovic F., Wade J.D. Solid-phase synthesis of europium-labeled human INSL3 as a novel probe for the study of ligand-receptor interactions. Bioconjug. Chem. 2008, 19:1456-1463.
18. Shabanpoor F., Hughes R.A., Zhang S., Bathgate R.A., Layfield S., Hossain M.A., Tregear G.W., Separovic F., Wade J.D. Effect of helix-promoting strategies on the biologic activity of novel analogs of the B-chain of INSL3. Amino Acids 2010, 38:121-131.
19. Hossain M.A., Rosengren K.J., Samuel C.S., Shabanpoor F., Chan L.J., Bathgate R.A., Wade J.D. The minimal active structure of human relaxin-2. J. Biol. Chem. 2011, 286:37555-37565.
20. Silvertown J.D., Symes J.C., Neschadim A., Nonaka T., Kao J.C., Summerlee A.J., Medin J.A. Analog of H2 relaxin exhibits antagonistic properties and impairs prostate tumor growth. Faseb J. 2007, 21:754-765.
21. Shabanpoor F., Separovic F., Wade J.D. General method for selective labeling of double-chain cysteine-rich peptides with a lanthanide chelate via solid-phase synthesis. J. Pept. Sci. 2011, 17:169-173.
22. Hossain M.A., Rosengren K.J., Haugaard-Jonsson L.M., Zhang S., Layfield S., Ferraro T., Daly N.L., Tregear G.W., Wade J.D., Bathgate R.A. The A-chain of human relaxin family peptides has distinct roles in the binding and activation of the different relaxin family peptide receptors. J. Biol. Chem. 2008, 283:17287-17297.